A

Arcellx Inc
NASDAQ:ACLX

Watchlist Manager
Arcellx Inc
NASDAQ:ACLX
Watchlist
Price: 71.86 USD -1.14% Market Closed
Market Cap: 4.2B USD
Section:
 

Relative Value

The Relative Value of one ACLX stock under the Base Case scenario is 48.16 USD. Compared to the current market price of 71.86 USD, Arcellx Inc is Overvalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACLX Relative Value
Base Case
48.16 USD
Overvaluation 33%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

115.7
P/S
P/S
Price to Sales
115.7
vs History
8
vs Industry
24
Median 3Y
35.5
Median 5Y
30.4
Industry
7.9
Forward
115.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-21
Median 5Y
-19.2
Industry
23.7
Forward
-16.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
11
Median 3Y
-14.5
Median 5Y
-10.9
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
-21.6
Median 5Y
-11.7
Industry
23.8
More Details
9.4
P/B
P/B
Price to Book Value
9.4
vs History
14
vs Industry
11
Median 3Y
7.2
Median 5Y
6.8
Industry
3.3
More Details
97
EV/S
EV/S
Enterprise Value to Sales
97
vs History
4
vs Industry
22
Median 3Y
27.9
Median 5Y
25.7
Industry
8.3
Forward
102
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-15.2
Industry
6.4
Forward
-13.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-15.8
Median 5Y
-14.8
Industry
7
Forward
-13.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
12
Median 3Y
-12.1
Median 5Y
-7.8
Industry
8.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
9
Median 3Y
-11.9
Median 5Y
-7.3
Industry
6.5
More Details
18.3
EV/IC
EV/IC
Enterprise Value to IC
18.3
vs History
39
vs Industry
9
Median 3Y
19.1
Median 5Y
18.4
Industry
5.7
More Details

Multiples Across Competitors

ACLX Competitors Multiples
Arcellx Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arcellx Inc
NASDAQ:ACLX
3.9B USD 115.7 -19.1 -14.8 -14.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
400.7B USD 6.7 170.6 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
172.3B USD 4.8 24.6 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
149.8B USD 5.1 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 9.8 31.1 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52B USD 16.2 1 194.7 156.9 190.3
NL
argenx SE
XBRU:ARGX
42.9B EUR 14 32.9 56.5 58.1
P/S Multiple
Revenue Growth P/S to Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average P/S: 3 073 833.9
115.7
30%
3.9
FR
Pharnext SCA
OTC:PNEXF
33 809 907.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 083.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.2
46%
0.4
NL
argenx SE
XBRU:ARGX
14
49%
0.3
P/E Multiple
Earnings Growth PEG
US
A
Arcellx Inc
NASDAQ:ACLX
Average P/E: 188.6
Negative Multiple: -19.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 194.7
N/A N/A
NL
argenx SE
XBRU:ARGX
32.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average EV/EBITDA: 39
Negative Multiple: -14.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.9
N/A N/A
NL
argenx SE
XBRU:ARGX
56.5
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average EV/EBIT: 45.1
Negative Multiple: -14.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.1
N/A N/A

See Also

Summary
ACLX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACLX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACLX stock valuation using valuation multiples.
Wall Street Estimates
ACLX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACLX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.